• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, July 7, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in humans

Bioengineer by Bioengineer
July 19, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

These findings suggest that for therapies to be effective, they must be targeted at both gene products

IMAGE

Credit: CNIO

KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human tumours. The development of KRAS inhibitors is, thus, an extremely active line of research. Effective results have been elusive so far, though – no KRAS inhibitor had been available until a month ago, when the FDA granted approval to Sotorasib.

KRAS encodes two gene products, KRAS4A and KRAS4B, whose levels can vary across organs and embryonic stages. When KRAS mutates, both variants, or isoforms, are activated. Though, some studies have focussed on approaches to target only KRAS4B, since it usually found to be expressed at higher levels in tumours.

In this study, Matthias Drosten, Marina Salmón and Guillem Paniagua of the Experimental Oncology Programme, headed by Mariano Barbacid at the CNIO, had a more fundamental goal: to understand how the isoforms work separately. As they state in the paper to be published in PNAS, “The biological relevance of the expression of two isoforms has puzzled researchers for decades.”

Lung cancer and metastasis

A basic research project in principle, Drosten and Salmón’s study produced results that came as “a surprise.” Even though KRAS4B is the dominant form in cancer, the KRAS4A mutant is also oncogenic, and it is even more active.

In the words of the authors, “KRAS4AG12V alone, in the absence of KRAS4B, can induce lung cancer and metastasis in 20 percent of individuals. Our results suggest that for therapies to be effective, the two KRAS isoforms should be targeted.”

KRAS genes in embryonic development

The researchers at the CNIO created two genetically engineered mouse models that lacked KRAS4B and expressed the KRAS4A variant only, both with and without the G12V mutation (KRAS4AG12V).

In addition, the study explored the role of the two isoforms in embryonic development. One of them, KRAS4B, “is key after birth, since in the absence of this variant, mice cannot grow as a result of heart disease”.

The CNIO Experimental Oncology Group is a global reference studying KRAS-related cancers, with notable examples such as the elimination of lung tumors and advanced pancreatic tumors by inactivating the RAF1 kinase in animal models.

###

In this work Sagrario Ortega, head of the Mouse Genomic Editing Core Unit at the CNIO, Javier Muñoz, head of the CNIO Proteomics Core Unit and Eduardo Caleiras of the Histopathology Core Unit at the CNIO, contributed fundamentally. The research was funded by the Spanish Ministry of Science and Innovation, the Institute of Health Carlos III, the European Research Council (ERC), the Autonomous Community of Madrid, the Fundación CRIS Cancer and AXA Research Fund.

Media Contact
Department of Communications
[email protected]

Related Journal Article

http://dx.doi.org/10.1073/pnas.2023112118

Tags: BiologycancerCell BiologyClinical TrialsDisease in the Developing WorldGenesGeneticsHealth ProfessionalsMolecular Biology
Share12Tweet8Share2ShareShareShare2

Related Posts

COVID-19 stock image

Collaboration advances DNA-delivered antibodies to prevent COVID-19

July 7, 2022
Eat

Study finds people who practice intermittent fasting experience less severe complications from COVID-19

July 7, 2022

Less sex during menopause transition not linked to sexual pain

July 7, 2022

Climate factors predict future mosquito activity

July 6, 2022
Please login to join discussion

POPULAR NEWS

  • blank

    Telescopic contact lenses

    40 shares
    Share 16 Tweet 10
  • Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    38 shares
    Share 15 Tweet 10
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    37 shares
    Share 15 Tweet 9
  • Emerging Omicron subvariants BA.2.12.1, BA.4 and BA.5 are inhibited less efficiently by antibodies

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Zoology/Veterinary ScienceVirologyWeaponryUniversity of WashingtonVehiclesUrogenital SystemVirusWeather/StormsUrbanizationVaccinesVaccineViolence/Criminals

Recent Posts

  • Nanoparticle ‘backpacks’ restore damaged stem cells
  • A new giant dinosaur gives insight into why many prehistoric meat-eaters had such tiny arms
  • Led by Columbia Engineering, researchers build longest, highly conductive molecular nanowire 
  • The beginning of life: The early embryo is in the driver’s seat
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....